326 related articles for article (PubMed ID: 31877123)
21. Microtubules underlie dysfunction in duchenne muscular dystrophy.
Khairallah RJ; Shi G; Sbrana F; Prosser BL; Borroto C; Mazaitis MJ; Hoffman EP; Mahurkar A; Sachs F; Sun Y; Chen YW; Raiteri R; Lederer WJ; Dorsey SG; Ward CW
Sci Signal; 2012 Aug; 5(236):ra56. PubMed ID: 22871609
[TBL] [Abstract][Full Text] [Related]
22. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.
Moulton HM; Moulton JD
Biochim Biophys Acta; 2010 Dec; 1798(12):2296-303. PubMed ID: 20170628
[TBL] [Abstract][Full Text] [Related]
23. Dystrophic Dmd
Krishnan VS; Thanigaiarasu LP; White R; Crew R; Larcher T; Le Guiner C; Grounds MD
Mol Cell Neurosci; 2020 Oct; 108():103549. PubMed ID: 32890728
[TBL] [Abstract][Full Text] [Related]
24. Brain function in Duchenne muscular dystrophy.
Anderson JL; Head SI; Rae C; Morley JW
Brain; 2002 Jan; 125(Pt 1):4-13. PubMed ID: 11834588
[TBL] [Abstract][Full Text] [Related]
25. PDGFRα signalling promotes fibrogenic responses in collagen-producing cells in Duchenne muscular dystrophy.
Ieronimakis N; Hays A; Prasad A; Janebodin K; Duffield JS; Reyes M
J Pathol; 2016 Dec; 240(4):410-424. PubMed ID: 27569721
[TBL] [Abstract][Full Text] [Related]
26. MyD88 is required for satellite cell-mediated myofiber regeneration in dystrophin-deficient mdx mice.
Gallot YS; Straughn AR; Bohnert KR; Xiong G; Hindi SM; Kumar A
Hum Mol Genet; 2018 Oct; 27(19):3449-3463. PubMed ID: 30010933
[TBL] [Abstract][Full Text] [Related]
27. Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
Terrill JR; Pinniger GJ; Graves JA; Grounds MD; Arthur PG
J Physiol; 2016 Jun; 594(11):3095-110. PubMed ID: 26659826
[TBL] [Abstract][Full Text] [Related]
28. Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy.
Renzini A; Marroncelli N; Cavioli G; Di Francescantonio S; Forcina L; Lambridis A; Di Giorgio E; Valente S; Mai A; Brancolini C; Giampietri C; Magenta A; De Santa F; Adamo S; Coletti D; Moresi V
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1339-1359. PubMed ID: 35170869
[TBL] [Abstract][Full Text] [Related]
29. Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment.
González-Sánchez J; Sánchez-Temprano A; Cid-Díaz T; Pabst-Fernández R; Mosteiro CS; Gallego R; Nogueiras R; Casabiell X; Butler-Browne GS; Mouly V; Relova JL; Pazos Y; Camiña JP
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1063-1078. PubMed ID: 30216693
[TBL] [Abstract][Full Text] [Related]
30. Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy.
Yoon SH; Grynpas M; Mitchell J
Bone; 2019 Apr; 121():232-242. PubMed ID: 30716510
[TBL] [Abstract][Full Text] [Related]
31. PTEN Inhibition Ameliorates Muscle Degeneration and Improves Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.
Yue F; Song C; Huang D; Narayanan N; Qiu J; Jia Z; Yuan Z; Oprescu SN; Roseguini BT; Deng M; Kuang S
Mol Ther; 2021 Jan; 29(1):132-148. PubMed ID: 33068545
[TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy.
Li H; Mittal A; Makonchuk DY; Bhatnagar S; Kumar A
Hum Mol Genet; 2009 Jul; 18(14):2584-98. PubMed ID: 19401296
[TBL] [Abstract][Full Text] [Related]
33. Acute AT
Meyers TA; Heitzman JA; Krebsbach AM; Aufdembrink LM; Hughes R; Bartolomucci A; Townsend D
J Mol Cell Cardiol; 2019 Mar; 128():51-61. PubMed ID: 30664850
[TBL] [Abstract][Full Text] [Related]
34. Small-molecule activation of lysosomal TRP channels ameliorates Duchenne muscular dystrophy in mouse models.
Yu L; Zhang X; Yang Y; Li D; Tang K; Zhao Z; He W; Wang C; Sahoo N; Converso-Baran K; Davis CS; Brooks SV; Bigot A; Calvo R; Martinez NJ; Southall N; Hu X; Marugan J; Ferrer M; Xu H
Sci Adv; 2020 Feb; 6(6):eaaz2736. PubMed ID: 32128386
[TBL] [Abstract][Full Text] [Related]
35. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice.
Burkin DJ; Wallace GQ; Nicol KJ; Kaufman DJ; Kaufman SJ
J Cell Biol; 2001 Mar; 152(6):1207-18. PubMed ID: 11257121
[TBL] [Abstract][Full Text] [Related]
36. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
[TBL] [Abstract][Full Text] [Related]
37. Hsp72 preserves muscle function and slows progression of severe muscular dystrophy.
Gehrig SM; van der Poel C; Sayer TA; Schertzer JD; Henstridge DC; Church JE; Lamon S; Russell AP; Davies KE; Febbraio MA; Lynch GS
Nature; 2012 Apr; 484(7394):394-8. PubMed ID: 22495301
[TBL] [Abstract][Full Text] [Related]
38. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy.
Ito M; Ehara Y; Li J; Inada K; Ohno K
Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975
[TBL] [Abstract][Full Text] [Related]
39. Bowman-Birk inhibitor attenuates dystrophic pathology in mdx mice.
Morris CA; Selsby JT; Morris LD; Pendrak K; Sweeney HL
J Appl Physiol (1985); 2010 Nov; 109(5):1492-9. PubMed ID: 20847128
[TBL] [Abstract][Full Text] [Related]
40. Muscle ERRγ mitigates Duchenne muscular dystrophy via metabolic and angiogenic reprogramming.
Matsakas A; Yadav V; Lorca S; Narkar V
FASEB J; 2013 Oct; 27(10):4004-16. PubMed ID: 23781095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
